ArticleFrontiers in oncology2025
Diagnostic value of exosome non-coding RNAs as non-invasive biomarkers in gastric cancer: a meta-analysis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Liquid biopsy biomarkers for early detection of gastrointestinal cancers: Current landscape and emerging technologies.Clinical and translational medicine · 2026Review
- Exosome-derived miR-BART2-5p and miR-BART11-5p induced epithelial-mesenchymal transition and migration in Epstein-Barr virus-associated gastric carcinoma.Journal of molecular histology · 2026Article
- In silico analysis suggests ELL2 as a survival-associated cross-tissue biomarker in gastric cancer.Cancer biomarkers : section A of Disease markersArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Gastric cancer, characterised by a significant mortality rate, is one of the most prevalent malignant neoplasms globally. Exosomal non-coding RNAs play a key role in gastric carcinogenesis, metastasis and treatment resistance by regulating gene expression, remodelling the tumour microenvironment and mediating drug resistance. In the identification of early gastric cancer, these exosomal non-coding RNA molecules possess significant potential to be developed into biomarkers that do not entail invasive procedures. Methods: Our study undertook a comprehensive and profound literature examination in core databases like PubMed, Web of Science, ScienceDirect, Embase, Scopus, and Medline, with the aim of precisely evaluating the potential effectiveness of exosomal miRNAs, lncRNAs, and circRNAs in the diagnosis of gastric cancer. Results: A sum of 52 studies were incorporated, comprising 164 studies. These studies identified a total of 59 miRNAs, 17 lncRNAs, and 16 circRNAs. For miRNAs, sensitivity was estimated at 0.72 (95% CI, 0.69 - 0.76) and specificity at 0.80 (95% CI, 0.77 - 0.83). For lncRNAs, the sensitivity was 0.86 (95% CI, 0.84 - 0.87) and the specificity was 0.82 (95% CI, 0.80 - 0.83). In the case of circRNAs, the sensitivity and specificity were 0.71 (95% CI, 0.63 - 0.78) and 0.88 (95% CI, 0.81 - 0.93) respectively. The AUC for miRNAs was calculated as 0.83. As for lncRNAs, its AUC was established to be 0.89. Regarding circRNAs, the determined AUC was 0.86. Conclusion: These results confirm the efficacy of exosomal ncRNAs as powerful biomarkers for the early diagnosis of gastric carcinomas, thereby laying a strong foundation for the advancement of novel diagnostic approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.